Microfluidic Devices Market in the Healthcare Industry to 2015

2013-01-22
Published : Jan-2013

TechNavio”s analysts forecast the Global Microfluidic Devices market in the Healthcare industry to grow at a CAGR of 26.7 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing use of microfluidic devices in proteomics and genomics. The Global Microfluidic Devices market in the Healthcare industry has also been witnessing the trend of the increasing use of microfluidic devices in drug discovery. However, the intense competition among vendors could pose a challenge to the growth of this market.

TechNavio”s report, the Global Microfluidic Devices Market in the Healthcare Industry 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Monoclonal Antibodies market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Fluidigm Corp., RainDance Technologies Inc., Agilent Technologies Inc., and Dolomite Centre Ltd.

The other vendors mentioned in the report are Micronit Microfluidics BV, Illumina Inc., MicruX Technologies Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, BioFluidix GmbH, Abaxis Inc., Advion Biosciences Inc., Caliper Life Sciences Inc., Cepheid Inc., Danaher Corp., Eksigent Technologies Inc., GE Novasensor Inc., Illumina Inc., Johnson and Johnson, Konica Minolta Holdings Inc., Microfluidic Systems Inc., Life Technologies Corp., Philips Healthcare, Roche Diagnostics, Shimadzu Biotech, and Siemens Healthcare.

Key questions answered in this report:
What will the market size be in 2015 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.

TechNavio”s research portfolio in the Healthcare series includes reports on the Pharmaceutical Market, Medical Devices Market, Diagnostic Market, Vaccine Market, Oncology Market, CRO Market, Orthopedic Market, Hearing Aids Market, Dental Care Market, Medical Imaging Market, Endoscopy Market, Dialysis Market, Telemedicine Market, Cancer Drug Market, Glucose Monitoring Market, Infusion Pumps Market, Defibrillators Market, Neuromodulation Market, Capnography Market.

Buy a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=212064.

Table of Contents

01. Executive Summary
02. Introduction
03. Market Coverage
Market Overview
Product Offerings
04. Market Landscape
Market Size and Forecast
04.1 Market Segmentation by Application
04.2 Five Forces Analysis
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and Their Impact
09. Market Challenges
10. Impact of Drivers and Challenges
11. Market Trends
12. Key Vendor Analysis
12.1 Fluidigm Corp.
Business Overview
Key Information
SWOT Analysis
12.2 RainDance Technologies Inc.
Business Overview
Key Information
SWOT Analysis
12.3 Agilent Technologies Inc.
Business Overview
Key Information
SWOT Analysis
12.4 Dolomite Centre Ltd.
Business Overview
Key Information
SWOT Analysis
13. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Microfluidic Devices Market in the Healthcare Industry 2011-2015 (US$ million)
Exhibit 2: Global Microfluidic Devices Market in the Healthcare Industry Segmentation by Application 2011
Exhibit 3: Global Microfluidic Devices Market in the Healthcare Industry Segmentation 2011-2015 (in percent)
Exhibit 4: Global Microfluidic Devices Market in the Healthcare Industry Segmentation 2011-2015 (in US$ million)
Exhibit 5: Global Microfluidic Devices Market in the Healthcare Industry by Vendor Segmentation (by revenue) 2011

Contact sales@reportsandreports.com for further information.

Filed in: Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Russia

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Russia. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts. In 2016, Russia population was approxi......
$1995

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Helminthiasis Global Clinical Trials Review, H2, 2017

Helminthiasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthiasis Global Clinical Trials Review, H2, 2017" provides an overview of Helminthiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500